Abstract
Cytopathologic identification of circulating tumor cells (CTCs) in breast cancer: Application of size-based enrichment
Highlights
Breast cancer is the most commonly diagnosed malignancy as well as a leading cause of cancer-related mortality among women globally [1]
The prevalence of Circulating tumor cells (CTCs) is indicative of metastatic disease and associated with poorer clinical outcomes in multiple types of malignancies [4,5,6]
CTC enrichment: CTCs were isolated from 10 mL of peripheral blood following the protocol described by ISET® (RareCells, Paris, France)
Summary
Breast cancer is the most commonly diagnosed malignancy as well as a leading cause of cancer-related mortality among women globally [1]. While prevention of recurrence is the primary goal for early-stage breast cancer, palliative care to alleviate symptoms and extension of survival time become the primary focus in metastatic disease. Accurate prediction of prognosis, as well as early detection of metastatic disease, are crucial for clinical management. Circulating tumor cells (CTCs) have been highlighted as a “liquid biopsy,” enabling non-invasive longitudinal disease monitoring [2,3]. CTCs are mediators of hematogenous metastasis, through which viable cancer cells from the primary tumor enter the circulation and infiltrate distant organs. Numerous studies have followed, investigating the clinical validity of CTCs in the prediction of prognosis [3,7,8,9] and therapy response [3,10,11]. Given the conceptual validity of CTCs as a prognostic marker, a number of new technologies for the detection of CTCs have emerged [12]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
